Core Insights - Royalty Pharma has made a significant announcement regarding its ambitions in Asia, particularly in China, by hiring Ken Sun as the new Head of Asia [1] Company Developments - Ken Sun, previously the Head of Asia Pacific Healthcare Investment Banking at Morgan Stanley, has been recruited, which is seen as a major achievement for Royalty Pharma [1] - The hiring of Ken Sun is expected to enhance Royalty Pharma's capabilities in pursuing licensing deals in China, indicating a strategic focus on expanding its presence in the Asian market [1]